Lactate transporters and pH regulation: Potential therapeutic targets in glioblastomas

Current Cancer Drug Targets

Volumn 16, Issue 5, 2016, Pages 388-399

  Miranda Gonçalves, Vera ^a,b   Reis, Rui M ^a,b,c   Baltazar, Fátima ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c BARRETOS CANCER HOSPITAL   (Brazil)

Author keywords

Acidic microenvironment; Carbonic anhydrases (CAs); Glioblastomas; Lactate; Monocarboxylate transporters (MCTs); pH regulators; Warburg effect

Indexed keywords

6 PHOSPHOFRUCTOKINASE; AZD3965; BEVACIZUMAB; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE XII; COUMARIN; GIRENTUXIMAB; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; INTERLEUKIN 8; LACTATE DEHYDROGENASE; LACTATE TRANSPORTER; LACTIC ACID; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4; NILOTINIB; PEPTIDES AND PROTEINS; PH REGULATOR; PHOSPHOGLUCONATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE; SULFONAMIDE; TRANSKETOLASE; UNCLASSIFIED DRUG; VASCULOTROPIN; MONOCARBOXYLATE TRANSPORTER;

ACIDOSIS; ARTICLE; BLOOD BRAIN BARRIER; CELL PH; CITRIC ACID CYCLE; DRUG TARGETING; GLIOBLASTOMA; HUMAN; NONHUMAN; OVERALL SURVIVAL; PENTOSE PHOSPHATE CYCLE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BRAIN TUMOR; GLYCOLYSIS; METABOLISM; PH; PHYSIOLOGY;

ANIMALS; BRAIN NEOPLASMS; CARBONIC ANHYDRASES; GLIOBLASTOMA; GLYCOLYSIS; HUMANS; HYDROGEN-ION CONCENTRATION; LACTIC ACID; MONOCARBOXYLIC ACID TRANSPORTERS; UP-REGULATION;

EID: 84973664272     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009616666151222150543     Document Type: Article

References (121)

1. Louis, D. N.; Ohgaki, H.; Wiestler, O. D.; Cavenee, W. K.; Burger, P. C.; Jouvet, A.; Scheithauer, B. W.; Kleihues, P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica, 2007, 114(2), 97-109.
2. Rosenblum, M. K. The 2007 WHO Classification of Nervous System Tumors: newly recognized members of the mixed glioneuronal group. Brain Pathol., 2007, 17(3), 308-813.
3. Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R. C.; Ludwin, S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; Eisenhauer, E.; Mirimanoff, R. O.; European Organisation for, R.; Treatment of Cancer Brain, T.; Radiotherapy, G. National Cancer Institute of Canada Clinical Trials, G. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352(10), 987-996.
4. Bai, R. Y.; Staedtke, V.; Riggins, G. J. Molecular targeting of glioblastoma: Drug discovery and therapies. Trends Mol. Med., 2011, 17(6), 301-312.
5. Lai, A.; Tran, A.; Nghiemphu, P. L.; Pope, W. B.; Solis, O. E.; Selch, M.; Filka, E.; Yong, W. H.; Mischel, P. S.; Liau, L. M.; Phuphanich, S.; Black, K.; Peak, S.; Green, R. M.; Spier, C. E.; Kolevska, T.; Polikoff, J.; Fehrenbacher, L.; Elashoff, R.; Cloughesy, T. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol., 2011, 29(2), 142-148.
6. Chinot, O. L.; Wick, W.; Mason, W.; Henriksson, R.; Saran, F.; Nishikawa, R.; Carpentier, A. F.; Hoang-Xuan, K.; Kavan, P.; Cernea, D.; Brandes, A. A.; Hilton, M.; Abrey, L.; Cloughesy, T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med., 2014, 370(8), 709-722.
7. Weathers, S. P. and Gilbert, M. R. Advances in treating glioblastoma. F1000prime Reports, 2014, 6, 46.
8. Gaspar, N.; Marshall, L.; Perryman, L.; Bax, D. A.; Little, S. E.; Viana-Pereira, M.; Sharp, S. Y.; Vassal, G.; Pearson, A. D.; Reis, R. M.; Hargrave, D.; Workman, P.; Jones, C. MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res., 2010, 70(22), 9243-9252.
9. Costa, B. M.; Caeiro, C.; Guimaraes, I.; Martinho, O.; Jaraquemada, T.; Augusto, I.; Castro, L.; Osorio, L.; Linhares, P.; Honavar, M.; Resende, M.; Braga, F.; Silva, A.; Pardal, F.; Amorim, J.; Nabico, R.; Almeida, R.; Alegria, C.; Pires, M.; Pinheiro, C.; Carvalho, E.; Lopes, J. M.; Costa, P.; Damasceno, M.; Reis, R. M. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. Oncol. Rep., 2010, 23(6), 1655-1662.
10. Vander Heiden, M. G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov., 2011, 10(9), 671-684.
11. DeBerardinis, R. J.; Lum, J. J.; Hatzivassiliou, G.; Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab., 2008, 7(1), 11-20.
12. DeBerardinis, R. J.; Thompson, C. B. Cellular metabolism and disease: what do metabolic outliers teach us? Cell, 2012, 148(6), 1132-1144.
13. Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 2009, 324(5930), 1029-1033.
14. Schulze, A.; Harris, A. L. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature, 2012, 491(7424), 364-373.
15. Tennant, D. A.; Duran, R. V.; Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nature Rev. Cancer, 2010, 10(4), 267-277.
16. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell, 2011, 144(5), 646-674.
17. Warburg, O. On respiratory impairment in cancer cells. Science, 1956, 124(3215), 269-270.
18. Cairns, R. A.; Harris, I. S.; Mak, T. W. Regulation of cancer cell metabolism. Nat. Rev. Cancer, 2011, 11(2), 85-95.
19. Gatenby, R. A.; Gillies, R. J. Why do cancers have high aerobic glycolysis? Nature Rev. Cancer, 2004, 4(11), 891-899.
20. Deberardinis, R. J.; Sayed, N.; Ditsworth, D.; Thompson, C. B. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Develop., 2008, 18(1), 54-61.
21. Hirschhaeuser, F.; Sattler, U. G.; Mueller-Klieser, W. Lactate: a metabolic key player in cancer. Cancer Res., 2011, 71(22), 6921-6925.
22. Wolf, A.; Agnihotri, S.; Guha, A. Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget., 2010, 1(7), 552-562.
23. DeBerardinis, R. J.; Mancuso, A.; Daikhin, E.; Nissim, I.; Yudkoff, M.; Wehrli, S.; Thompson, C. B. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Nat. Acad. Sci. USA, 2007, 104(49), 19345-19350.
24. Miranda-Gonçalves, V.; Reis, R. M.; Baltazar, F. Brain Tumor Metabolism: unraveling its role in finding new therapeutic targets. In Molecular considerations and evolving surgical management issues in the treatment of patients with a brain tumor, Terry Lichtor Edition ed.; InTech, Ed. 2015; pp 83-102.
25. Dhup, S.; Dadhich, R. K.; Porporato, P. E.; Sonveaux, P. Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr. Pharm. Design, 2012, 18(10), 1319-1330.
26. Porporato, P. E.; Dhup, S.; Dadhich, R. K.; Copetti, T.; Sonveaux, P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front. Pharmacol., 2011, 2, 49.
27. Neri, D.; Supuran, C. T. Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discov., 2011, 10(10), 767-777.
28. Parks, S. K.; Chiche, J.; Pouyssegur, J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat. Rev. Cancer, 2013, 13(9), 611-623.
29. Draoui, N.; Feron, O. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis Models Mechanisms, 2011, 4(6), 727-732.
30. Pellerin, L. Lactate as a pivotal element in neuron-glia metabolic cooperation. Neurochem. Int., 2003, 43(4-5), 331-338.
31. Sonveaux, P.; Vegran, F.; Schroeder, T.; Wergin, M. C.; Verrax, J.; Rabbani, Z. N.; De Saedeleer, C. J.; Kennedy, K. M.; Diepart, C.; Jordan, B. F.; Kelley, M. J.; Gallez, B.; Wahl, M. L.; Feron, O.; Dewhirst, M. W. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest., 2008, 118(12), 3930-3942.
32. Semenza, G. L. Tumor metabolism: cancer cells give and take lactate. J. Clin. Invest., 2008, 118(12), 3835-3837.
33. Walenta, S.; Mueller-Klieser, W. F. Lactate: mirror and motor of tumor malignancy. Sem. Radiation Oncol., 2004, 14(3), 267-274.
34. Fulham, M. J.; Bizzi, A.; Dietz, M. J.; Shih, H. H.; Raman, R.; Sobering, G. S.; Frank, J. A.; Dwyer, A. J.; Alger, J. R.; Di Chiro, G. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology, 1992, 185(3), 675-686.
35. Stern, R.; Shuster, S.; Neudecker, B. A.; Formby, B. Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. Exp. Cell Res., 2002, 276(1), 24-31.
36. Baumann, F.; Leukel, P.; Doerfelt, A.; Beier, C. P.; Dettmer, K.; Oefner, P. J.; Kastenberger, M.; Kreutz, M.; Nickl-Jockschat, T.; Bogdahn, U.; Bosserhoff, A. K.; Hau, P. Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neuro-oncol., 2009, 11(4), 368-380.
37. Shi, Q.; Abbruzzese, J. L.; Huang, S.; Fidler, I. J.; Xiong, Q.; Xie, K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin. Cancer Res., 1999, 5(11), 3711-3721.
38. Shi, Q.; Le, X.; Wang, B.; Abbruzzese, J. L.; Xiong, Q.; He, Y.; Xie, K. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene, 2001, 20(28), 3751-3756.
39. Kato, Y.; Ozawa, S.; Tsukuda, M.; Kubota, E.; Miyazaki, K.; St-Pierre, Y.; Hata, R. Acidic extracellular pH increases calcium influx-triggered phospholipase D activity along with acidic sphingomyelinase activation to induce matrix metalloproteinase-9 expression in mouse metastatic melanoma. FEBS J., 2007, 274(12), 3171-3183.
40. Sedlakova, O.; Svastova, E.; Takacova, M.; Kopacek, J.; Pastorek, J.; Pastorekova, S. Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Front. Physiol., 2014, 4, 400.
41. Barar, J.; Omidi, Y. Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy. Bio Impacts, 2013, 3(4), 149-162.
42. Chiche, J.; Ilc, K.; Laferriere, J.; Trottier, E.; Dayan, F.; Mazure, N. M.; Brahimi-Horn, M. C.; Pouyssegur, J. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res., 2009, 69(1), 358-368.
43. Supuran, C. T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Rev. Drug Discov., 2008, 7(2), 168-181.
44. Chiche, J.; Ricci, J. E.; Pouyssegur, J. Tumor hypoxia and metabolism-towards novel anticancer approaches. Annal. d'endocrinologie, 2013, 74(2), 111-114.
45. Proescholdt, M. A.; Merrill, M. J.; Stoerr, E. M.; Lohmeier, A.; Pohl, F.; Brawanski, A. Function of carbonic anhydrase IX in glioblastoma multiforme. Neuro-oncology, 2012, 14(11), 1357-1366.
46. Zatovicova, M.; Jelenska, L.; Hulikova, A.; Csaderova, L.; Ditte, Z.; Ditte, P.; Goliasova, T.; Pastorek, J.; Pastorekova, S. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr. Pharm. Design, 2010, 16(29), 3255-3263.
47. Currie, M. J.; Beardsley, B. E.; Harris, G. C.; Gunningham, S. P.; Dachs, G. U.; Dijkstra, B.; Morrin, H. R.; Wells, J. E.; Robinson, B. A. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity. Human Pathol., 2013, 44(3), 402-411.
48. McIntyre, A.; Patiar, S.; Wigfield, S.; Li, J. L.; Ledaki, I.; Turley, H.; Leek, R.; Snell, C.; Gatter, K.; Sly, W. S.; Vaughan-Jones, R. D.; Swietach, P.; Harris, A. L. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin. Cancer Res., 2012, 18(11), 3100-3111.
49. Paschen, W.; Djuricic, B.; Mies, G.; Schmidt-Kastner, R.; Linn, F. Lactate and pH in the brain: association and dissociation in different pathophysiological states. J. Neurochem., 1987, 48(1), 154-159.
50. Halestrap, A. P.; Price, N. T. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem. J., 1999, 343, 281-299.
51. Enerson, B. E.; Drewes, L. R. Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J. Pharm. Sci., 2003, 92(8), 1531-1544.
52. Halestrap, A. P.; Meredith, D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Archiv.: Eur. J. Physiol., 2004, 447(5), 619-628.
53. Merezhinskaya, N.; Fishbein, W. N. Monocarboxylate transporters: past, present, and future. Histol. Histopathol., 2009, 24(2), 243-264.
54. Brooks, G. A. Lactate: link between glycolytic and oxidative metabolism. Sports Med., 2007, 37(4-5), 341-343.
55. Pellerin, L.; Bergersen, L. H.; Halestrap, A. P.; Pierre, K. Cellular and subcellular distribution of monocarboxylate transporters in cultured brain cells and in the adult brain. J. Neurosci. Res., 2005, 79(1-2), 55-64.
56. Rafiki, A.; Boulland, J. L.; Halestrap, A. P.; Ottersen, O. P.; Bergersen, L. Highly differential expression of the monocarboxylate transporters MCT2 and MCT4 in the developing rat brain. Neurosci., 2003, 122(3), 677-688.
57. Pierre, K.; Pellerin, L. Monocarboxylate transporters in the central nervous system: distribution, regulation and function. J. Neurochem., 2005, 94(1), 1-14.
58. Pellerin, L.; Pellegri, G.; Martin, J. L.; Magistretti, P. J. Expression of monocarboxylate transporter mRNAs in mouse brain: support for a distinct role of lactate as an energy substrate for the neonatal vs. adult brain. Proc. Nat. Acad. Sci. USA, 1998, 95(7), 3990-3995.
59. Debernardi, R.; Pierre, K.; Lengacher, S.; Magistretti, P. J.; Pellerin, L. Cell-specific expression pattern of monocarboxylate transporters in astrocytes and neurons observed in different mouse brain cortical cell cultures. J. Neurosci. Res., 2003, 73(2), 141-155.
60. Kennedy, K. M.; Dewhirst, M. W. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol., 2010, 6(1), 127-148.
61. Vijay, N.; Morris, M. E. Role of monocarboxylate transporters in drug delivery to the brain. Curr. Pharm. Design, 2014, 20(10), 1487-1498.
62. Deguchi, Y.; Yokoyama, Y.; Sakamoto, T.; Hayashi, H.; Naito, T.; Yamada, S.; Kimura, R. Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier. Life Sci., 2000, 66(7), 649-662.
63. Pinheiro, C.; Longatto-Filho, A.; Azevedo-Silva, J.; Casal, M.; Schmitt, F. C.; Baltazar, F. Role of monocarboxylate transporters in human cancers: state of the art. J. Bioenerg. Biomembranes, 2012, 44(1), 127-139.
64. Queiros, O.; Preto, A.; Pacheco, A.; Pinheiro, C.; Azevedo-Silva, J.; Moreira, R.; Pedro, M.; Ko, Y. H.; Pedersen, P. L.; Baltazar, F.; Casal, M. Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate. J. Bioenerg. Biomembranes, 2012, 44(1), 141-153.
65. Afonso, J.; Santos, L. L.; Miranda-Goncalves, V.; Morais, A.; Amaro, T.; Longatto-Filho, A.; Baltazar, F. CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance. Mol. Carcinogenesis, 2015, 54(11), 1451-1466
66. Pinheiro, C.; Longatto-Filho, A.; Soares, T. R.; Pereira, H.; Bedrossian, C.; Michael, C.; Schmitt, F. C.; Baltazar, F. CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma. Diagnostic Cytopathol., 2012, 40(6), 478-483.
67. Alves, V. A.; Pinheiro, C.; Morais-Santos, F.; Felipe-Silva, A.; Longatto-Filho, A.; Baltazar, F. Characterization of monocarboxylate transporter activity in hepatocellular carcinoma. World J. Gastroenterol., 2014, 20(33), 11780-11787.
68. Pinheiro, C.; Penna, V.; Morais-Santos, F.; Abrahao-Machado, L. F.; Ribeiro, G.; Curcelli, E. C.; Olivieri, M. V.; Morini, S.; Valenca, I.; Ribeiro, D.; Schmitt, F. C.; Reis, R. M.; Baltazar, F. Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization. J. Transl. Med., 2014, 12, 118.
69. de Oliveira, A. T.; Pinheiro, C.; Longatto-Filho, A.; Brito, M. J.; Martinho, O.; Matos, D.; Carvalho, A. L.; Vazquez, V. L.; Silva, T. B.; Scapulatempo, C.; Saad, S. S.; Reis, R. M.; Baltazar, F. Coexpression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs). J. Bioenerg. Biomembranes, 2012, 44(1), 171-178.
70. Morais-Santos, F.; Miranda-Goncalves, V.; Pinheiro, S.; Vieira, A. F.; Paredes, J.; Schmitt, F. C.; Baltazar, F.; Pinheiro, C. Differential sensitivities to lactate transport inhibitors of breast cancer cell lines. Endocr. Relat. Cancer, 2014, 21(1), 27-38.
71. Pertega-Gomes, N.; Vizcaino, J. R.; Attig, J.; Jurmeister, S.; Lopes, C.; Baltazar, F. A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer, 2014, 14, 352.
72. Pinheiro, C.; Garcia, E. A.; Morais-Santos, F.; Scapulatempo-Neto, C.; Mafra, A.; Steenbergen, R. D.; Boccardo, E.; Villa, L. L.; Baltazar, F.; Longatto-Filho, A. Lactate transporters and vascular factors in HPV-induced squamous cell carcinoma of the uterine cervix. BMC Cancer, 2014, 14, 751.
73. Valenca, I.; Pertega-Gomes, N.; Vizcaino, J. R.; Henrique, R. M.; Lopes, C.; Baltazar, F.; Ribeiro, D. Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer. J. Cell. Mol. Med., 2015, 19(4), 723-733.
74. Martins, D.; Beca, F. F.; Sousa, B.; Baltazar, F.; Paredes, J.; Schmitt, F. Loss of caveolin-1 and gain of MCT4 expression in the tumor stroma: key events in the progression from an in situ to an invasive breast carcinoma. Cell Cycle, 2013, 12(16), 2684-2690.
75. Pertega-Gomes, N.; Vizcaino, J. R.; Gouveia, C.; Jeronimo, C.; Henrique, R. M.; Lopes, C.; Baltazar, F. Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. Prostate, 2013, 73(7), 763-769.
76. Miranda-Goncalves, V.; Honavar, M.; Pinheiro, C.; Martinho, O.; Pires, M. M.; Pinheiro, C.; Cordeiro, M.; Bebiano, G.; Costa, P.; Palmeirim, I.; Reis, R. M.; Baltazar, F. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro-oncology, 2013, 15(2), 172-188.
77. Amorim, R.; Pinheiro, C.; Miranda-Goncalves, V.; Pereira, H.; Moyer, M. P.; Preto, A.; Baltazar, F. Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells. Cancer Lett., 2015, 365(1), 68-78.
78. Froberg, M. K.; Gerhart, D. Z.; Enerson, B. E.; Manivel, C.; Guzman-Paz, M.; Seacotte, N.; Drewes, L. R. Expression of monocarboxylate transporter MCT1 in normal and neoplastic human CNS tissues. Neuroreport, 2001, 12(4), 761-765.
79. Mathupala, S. P.; Parajuli, P.; Sloan, A. E. Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study. Neurosurgery, 2004, 55 (6), 1410-9; discussion 1419.
80. Fang, J.; Quinones, Q. J.; Holman, T. L.; Morowitz, M. J.; Wang, Q.; Zhao, H.; Sivo, F.; Maris, J. M.; Wahl, M. L. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol. Pharm., 2006, 70(6), 2108-2115.
81. Li, K. K.; Pang, J. C.; Ching, A. K.; Wong, C. K.; Kong, X.; Wang, Y.; Zhou, L.; Chen, Z.; Ng, H. K. miR-124 is frequently downregulated in medulloblastoma and is a negative regulator of SLC16A1. Human Pathol., 2009, 40(9), 1234-1243.
82. Colen, C. B.; Shen, Y.; Ghoddoussi, F.; Yu, P.; Francis, T. B.; Koch, B. J.; Monterey, M. D.; Galloway, M. P.; Sloan, A. E.; Mathupala, S. P. Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia, 2011, 13(7), 620-632.
83. Colen, C. B.; Seraji-Bozorgzad, N.; Marples, B.; Galloway, M. P.; Sloan, A. E.; Mathupala, S. P. Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study. Neurosurgery, 2006, 59(6), 1313-1323; discussion 1323-4.
84. Cheng, C.; Edin, N. F.; Lauritzen, K. H.; Aspmodal, I.; Christoffersen, S.; Jian, L.; Rasmussen, L. J.; Pettersen, E. O.; Xiaoqun, G.; Bergersen, L. H. Alterations of monocarboxylate transporter densities during hypoxia in brain and breast tumour cells. Cellular Oncol., 2012, 35(3), 217-227.
85. Monti, S. M.; Supuran, C. T.; De Simone, G. Anticancer carbonic anhydrase inhibitors: a patent review (2008-2013). Expert Opin. Ther. Patents, 2013, 23(6), 737-749.
86. De Simone, G.; Vitale, R. M.; Di Fiore, A.; Pedone, C.; Scozzafava, A.; Montero, J. L.; Winum, J. Y.; Supuran, C. T. Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J. Med. Chem., 2006, 49(18), 5544-5551.
87. Ahlskog, J. K.; Dumelin, C. E.; Trussel, S.; Marlind, J.; Neri, D. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioor. Med. Chem. Lett., 2009, 19(16), 4851-4856.
88. Buller, F.; Steiner, M.; Frey, K.; Mircsof, D.; Scheuermann, J.; Kalisch, M.; Buhlmann, P.; Supuran, C. T.; Neri, D. Selection of Carbonic Anhydrase IX Inhibitors from One Million DNAEncoded Compounds. ACS Chem. Biol., 2011, 6(4), 336-344.
89. Lou, Y.; McDonald, P. C.; Oloumi, A.; Chia, S.; Ostlund, C.; Ahmadi, A.; Kyle, A.; Auf dem Keller, U.; Leung, S.; Huntsman, D.; Clarke, B.; Sutherland, B. W.; Waterhouse, D.; Bally, M.; Roskelley, C.; Overall, C. M.; Minchinton, A.; Pacchiano, F.; Carta, F.; Scozzafava, A.; Touisni, N.; Winum, J. Y.; Supuran, C. T.; Dedhar, S. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res., 2011, 71(9), 3364-3376.
90. Maresca, A.; Temperini, C.; Vu, H.; Pham, N. B.; Poulsen, S. A.; Scozzafava, A.; Quinn, R. J.; Supuran, C. T. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J. Am. Chem. Soc., 2009, 131(8), 3057-3062.
91. Maresca, A.; Temperini, C.; Pochet, L.; Masereel, B.; Scozzafava, A.; Supuran, C. T. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J. Med. Chem., 2010, 53(1), 335-344.
92. Touisni, N.; Maresca, A.; McDonald, P. C.; Lou, Y.; Scozzafava, A.; Dedhar, S.; Winum, J. Y.; Supuran, C. T. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J. Med. Chem., 2011, 54(24), 8271-8277.
93. Chrastina, A.; Pastorekova, S.; Pastorek, J. Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumorassociated antigen by 125I-labeled M75 monoclonal antibody. Neoplasma, 2003, 50(1), 13-21.
94. Oosterwijk-Wakka, J. C.; Boerman, O. C.; Mulders, P. F.; Oosterwijk, E. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int. J. Mol. Sci., 2013, 14(6), 11402-11423.
95. Parkkila, S.; Innocenti, A.; Kallio, H.; Hilvo, M.; Scozzafava, A.; Supuran, C. T. The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms. Bioorg. Med. Chem. Lett., 2009, 19(15), 4102-4106.
96. Pouyssegur, J.; Dayan, F.; Mazure, N. M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature, 2006, 441(7092), 437-443.
97. Miranda-Gonçalves, V.; Baltazar, F.; Reis, R. M. Brain tumor metabolism: unraveling its role in finding new therapeutic targets. In Brain Tumors, Lichtor, T., Ed. InTech Open Access Publisher: In press.
98. Bueno, V.; Binet, I.; Steger, U.; Bundick, R.; Ferguson, D.; Murray, C.; Donald, D.; Wood, K. The specific monocarboxylate transporter (MCT1) inhibitor, AR-C117977, a novel immunosuppressant, prolongs allograft survival in the mouse. Transplantation, 2007, 84(9), 1204-1207.
99. Pertega-Gomes, N.; Felisbino, S.; Massie, C. E.; Vizcaino, J. R.; Coelho, R.; Sandi, C.; Simoes-Sousa, S.; Jurmeister, S.; Ramos-Montoya, A.; Asim, M.; Tran, M.; Oliveira, E.; Lobo da Cunha, A.; Maximo, V.; Baltazar, F.; Neal, D. E.; Fryer, L. G. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. J. Pathol., 2015, 236(4), 517-530.
100. Draoui, N.; Schicke, O.; Seront, E.; Bouzin, C.; Sonveaux, P.; Riant, O.; Feron, O. Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux. Mol. Cancer Therap., 2014, 13(6), 1410-1418.
101. Hanson, D. J.; Nakamura, S.; Amachi, R.; Hiasa, M.; Oda, A.; Tsuji, D.; Itoh, K.; Harada, T.; Horikawa, K.; Teramachi, J.; Miki, H.; Matsumoto, T.; Abe, M. Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation. Oncotarget., 2015, 6(32), 33568-33586.
102. Bola, B. M.; Chadwick, A. L.; Michopoulos, F.; Blount, K. G.; Telfer, B. A.; Williams, K. J.; Smith, P. D.; Critchlow, S. E.; Stratford, I. J. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol. Cancer Therap., 2014, 13(12), 2805-2816.
103. Polanski, R.; Hodgkinson, C. L.; Fusi, A.; Nonaka, D.; Priest, L.; Kelly, P.; Trapani, F.; Bishop, P. W.; White, A.; Critchlow, S. E.; Smith, P. D.; Blackhall, F.; Dive, C.; Morrow, C. J. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin. Cancer Res., 2014, 20(4), 926-937.
104. Marchiq, I.; Le Floch, R.; Roux, D.; Simon, M. P.; Pouyssegur, J. Genetic disruption of lactate/H+ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin. Cancer Res., 2015, 75(1), 171-180.
105. Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I. M.; Gallia, G. L.; Olivi, A.; McLendon, R.; Rasheed, B. A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D. A.; Tekleab, H.; Diaz, L. A., Jr.; Hartigan, J.; Smith, D. R.; Strausberg, R. L.; Marie, S. K.; Shinjo, S. M.; Yan, H.; Riggins, G. J.; Bigner, D. D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. An integrated genomic analysis of human glioblastoma multiforme. Science, 2008, 321(5897), 1807-1812.
106. Reitman, Z. J.; Yan, H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J. Nat. Cancer Inst., 2010, 102(13), 932-941.
107. Zhao, S.; Lin, Y.; Xu, W.; Jiang, W.; Zha, Z.; Wang, P.; Yu, W.; Li, Z.; Gong, L.; Peng, Y.; Ding, J.; Lei, Q.; Guan, K. L.; Xiong, Y. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science, 2009, 324(5924), 261-265.
108. Reitman, Z. J.; Duncan, C. G.; Poteet, E.; Winters, A.; Yan, L. J.; Gooden, D. M.; Spasojevic, I.; Boros, L. G.; Yang, S. H.; Yan, H. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. J. Biol. Chem., 2014, 289(34), 23318-23328.
109. Lamonte, G.; Tang, X.; Chen, J. L.; Wu, J.; Ding, C. K.; Keenan, M. M.; Sangokoya, C.; Kung, H. N.; Ilkayeva, O.; Boros, L. G.; Newgard, C. B.; Chi, J. T. Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress. Cancer Metab., 2013, 1(1), 23.
110. Corbet, C.; Draoui, N.; Polet, F.; Pinto, A.; Drozak, X.; Riant, O.; Feron, O. The SIRT1/HIF2alpha axis drives reductive glutamine metabolism under chronic acidosis and alters tumor response to therapy. Cancer Res., 2014, 74(19), 5507-5519.
111. Lau, D.; Magill, S. T.; Aghi, M. K. Molecularly targeted therapies for recurrent glioblastoma: current and future targets. Neurosurg. Focus, 2014, 37(6), E15.
112. Shah, A. H.; Graham, R.; Bregy, A.; Thambuswamy, M.; Komotar, R. J. Recognizing and correcting failures in glioblastoma treatment. Cancer Invest., 2014, 32(6), 299-302.
113. Verhaak, R. G.; Hoadley, K. A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M. D.; Miller, C. R.; Ding, L.; Golub, T.; Mesirov, J. P.; Alexe, G.; Lawrence, M.; O'Kelly, M.; Tamayo, P.; Weir, B. A.; Gabriel, S.; Winckler, W.; Gupta, S.; Jakkula, L.; Feiler, H. S.; Hodgson, J. G.; James, C. D.; Sarkaria, J. N.; Brennan, C.; Kahn, A.; Spellman, P. T.; Wilson, R. K.; Speed, T. P.; Gray, J. W.; Meyerson, M.; Getz, G.; Perou, C. M.; Hayes, D. N.; Cancer Genome Atlas Research, N. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 2010, 17(1), 98-110.
114. Calorini, L.; Peppicelli, S.; Bianchini, F. Extracellular acidity as favouring factor of tumor progression and metastatic dissemination. Exp. Oncol., 2012, 34(2), 79-84.
115. Oosterwijk, E.; Gillies, R. J. Targeting ion transport in cancer. Philosophical transactions of the Royal Society of London. Series B, Biol. Sci., 2014, 369(1638), 20130107.
116. Song, W. C.; Griffin, R.; Park, J. H. Influence of Tumor pH on Therapeutic Response. In Cancer Drug Resistance, Teicher, B. A., Ed. Humana Press: 2006; pp 21-42.
117. Stupp, R.; Gander, M.; Leyvraz, S.; Newlands, E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol., 2001, 2(9), 552-560.
118. Keunen, O.; Johansson, M.; Oudin, A.; Sanzey, M.; Rahim, S. A.; Fack, F.; Thorsen, F.; Taxt, T.; Bartos, M.; Jirik, R.; Miletic, H.; Wang, J.; Stieber, D.; Stuhr, L.; Moen, I.; Rygh, C. B.; Bjerkvig, R.; Niclou, S. P. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Nat. Acad. Sci. USA, 2011, 108(9), 3749-3754.
119. Curtarello, M.; Zulato, E.; Nardo, G.; Valtorta, S.; Guzzo, G.; Rossi, E.; Esposito, G.; Msaki, A.; Pasto, A.; Rasola, A.; Persano, L.; Ciccarese, F.; Bertorelle, R.; Todde, S.; Plebani, M.; Schroer, H.; Walenta, S.; Mueller-Klieser, W.; Amadori, A.; Moresco, R. M.; Indraccolo, S. VEGF-Targeted Therapy Stably Modulates the Glycolytic Phenotype of Tumor Cells. Cancer Res., 2015, 75(1), 120-133.
120. Fack, F.; Espedal, H.; Keunen, O.; Golebiewska, A.; Obad, N.; Harter, P. N.; Mittelbronn, M.; Bahr, O.; Weyerbrock, A.; Stuhr, L.; Miletic, H.; Sakariassen, P. O.; Stieber, D.; Rygh, C. B.; Lund-Johansen, M.; Zheng, L.; Gottlieb, E.; Niclou, S. P.; Bjerkvig, R. Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathol., 2015, 129(1), 115-131.
121. Hattingen, E.; Jurcoane, A.; Bahr, O.; Rieger, J.; Magerkurth, J.; Anti, S.; Steinbach, J. P.; Pilatus, U. Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neuro-oncol., 2011, 13(12), 1349-1363.